학술논문
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
Document Type
Abstract
Author
Source
In ESMO Open May 2023 8(1) Supplement 4
Subject
Language
ISSN
2059-7029